IN8bio (INAB) Noble Capital Markets’ Emerging Growth Virtual Equity Conference summary

Pipeline and clinical programs

• Two ongoing cell therapy programs: one for leukemia patients undergoing transplantation and one for glioblastoma, both showing patients beyond three years progression-free.

• INB-100 is enrolling an expansion cohort in leukemia, with updated phase I data expected by year-end.

• INB-200 and INB-400 target solid tumors, especially glioblastoma, using genetically modified gamma-delta T cells.

• INB-619 is a T cell engager platform targeting CD19, with potential in both oncology and autoimmune indications.

• Mouse data for INB-619 expected by late summer, which will trigger additional financing.

Glioblastoma clinical trial results

• Patients received up to six doses of modified gamma-delta T cells, with direct delivery into the tumor bed.

• Median progression-free survival for repeat dose patients reached 13 months, nearly double the control arm's 6.6 months.

• Median overall survival in treated patients is 17.2 months and still maturing, with some patients progression-free for over 4.6 years.

• No major toxicity signals or severe adverse events observed across multiple centers.

• 57% of treated patients remained progression-free longer than expected, compared to 10% in the control group.

Mechanism of action and innovation

• Therapy leverages the DNA damage response pathway to upregulate immune markers on tumor cells, enhancing immune targeting.

• Gamma-delta T cells are engineered to resist chemotherapy, allowing combined dosing and improved tumor cell eradication.

• Histopathology shows increased infiltration of immune cells in treated tumors.

• The approach is designed to address tumor heterogeneity and residual disease post-surgery.

• Potential applicability to other solid tumors due to the fundamental biology of the DNA damage response.